Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc ...

While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...

Obtaining regulatory approval for small-molecule therapeutics continues to be an arduous and expensive process. Because composition of matter patents are often filed long before first-patient-in, that ...

VERSUSstudio/Shutterstock.com Hardness is a key property of tablets and is assessed in all drug development stages. 3 The hardness of a tablet is determined by its crushing strength property, measured ...

Most drugs in the U.S. are taken orally because these oral dosage forms have a significant systemic effect on the body after being absorbed from different surfaces along the gastrointestinal tract ...

Integrating computational models (SELFormer, AlphaFold2, scConGraph, PROTAC-RL) with multi-omics data to validate historically undruggable targets (e.g., KRAS via ...

In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...

An update from Kazia Therapeutics ( ($KZIA) ) is now available. On December 2, 2025, Kazia Therapeutics announced a $50 million private placement ...